EMERALD: elacestrant vs. SOC for patients with ER+ HER2- metastatic breast cancer

EMERALD: elacestrant vs. SOC for patients with ER+ HER2- metastatic breast cancer

Treating ER+/HER2-low metastatic breast cancer, 2L and beyondПодробнее

Treating ER+/HER2-low metastatic breast cancer, 2L and beyond

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic BC without prior chemotherapy ptsПодробнее

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic BC without prior chemotherapy pts

Elacestrant shows improved PFS in patients with ER-positive/HER2-negative metastatic breast cancerПодробнее

Elacestrant shows improved PFS in patients with ER-positive/HER2-negative metastatic breast cancer

Update of EMERALD by duration of CDK4/6i in metastatic setting: elacestrant v SoC in ER+/HER2- mBCПодробнее

Update of EMERALD by duration of CDK4/6i in metastatic setting: elacestrant v SoC in ER+/HER2- mBC

SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBCПодробнее

SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC

EMERALD: elacestrant vs physicians choice in ER+/HER2- breast cancerПодробнее

EMERALD: elacestrant vs physicians choice in ER+/HER2- breast cancer